Showing results (491-500 of 527) with videos related to

Sort By:
Pageof 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2020
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206Hirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi, et al.
Cancer|February 2, 2016
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trialMasayuki Takeda, Takeharu Yamanaka, Takashi Seto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2015
Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung CancerYasuo Iwamoto, Tetsuya Mitsudomi, Kazuko Sakai, et al.
General Thoracic and Cardiovascular Surgery|April 26, 2019
Correction to: Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery, Hideyuki Shimizu, Shunsuke Endo, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|December 15, 2017
A proposal for a comprehensive risk scoring system for predicting postoperative complications in octogenarian patients with medically operable lung cancer: JACS1303Hisashi Saji, Takahiko Ueno, Hiroshige Nakamura, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 27, 2025
Quality comparison of mediastinal lymph node dissection between video-assisted thoracic surgery and open thoracotomy: a supplementary analysis of the phase 3 Japan Clinical Oncology Group 1413 trial†Norifumi Tsubokawa, Yasuhiro Tsutani, Tomoyuki Hishida, et al.
The Lancet. Oncology|October 5, 2019
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trialKen Kato, Byoung Chul Cho, Masanobu Takahashi, et al.
JTO Clinical and Research Reports|September 30, 2021
Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung AdenocarcinomaMasaoki Ito, Jordi Codony-Servat, Ana Giménez-Capitán, et al.
Cancer Science|December 28, 2021
Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1Kotoe Oshima, Ken Kato, Yoshinori Ito, et al.
JTO Clinical and Research Reports|November 29, 2023
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant ChemotherapyJunko Tanizaki, Hiroaki Kuroda, Toshihide Yokoyama, et al.
Pageof 53